Cryotherapy for recurrent prostate cancer after radiation therapy

Salvage Cryotherapy for Recurrent Prostate Cancer After Brachytherapy or Radiotherapy

NA · University Hospital Virgen de las Nieves · NCT04891536

This study is testing if a treatment called cryotherapy can be a safe and effective option for men with prostate cancer that comes back after radiation therapy.

Quick facts

PhaseNA
Study typeInterventional
Enrollment100 (estimated)
Ages18 Years to 90 Years
SexMale
SponsorUniversity Hospital Virgen de las Nieves (other)
Drugs / interventionsradiation
Locations2 sites (Córdoba, Andalucía and 1 other locations)
Trial IDNCT04891536 on ClinicalTrials.gov

What this trial studies

This project aims to create a comprehensive protocol for a multicenter registry of patients undergoing salvage cryoablation of the prostate (SCAP) for local recurrence of prostate cancer after radiation therapy. The study hypothesizes that SCAP is a safe and effective alternative to salvage radical prostatectomy, potentially offering lower morbidity with comparable efficacy. A systematic review has shown promising 2-year and 5-year biochemical recurrence-free survival rates, but there is a significant need for more robust evidence regarding long-term outcomes and side effects. The study will address these gaps by collecting detailed histopathological data and patient outcomes.

Who should consider this trial

Good fit: Ideal candidates include patients with histologically confirmed local recurrence of prostate cancer after radiation therapy, with no evidence of distant metastasis and specific clinical criteria.

Not a fit: Patients with clinically confirmed distant metastasis or significant urinary tract anomalies may not benefit from this treatment.

Why it matters

Potential benefit: If successful, this approach could provide a less invasive treatment option for patients with recurrent prostate cancer, potentially improving their quality of life and treatment outcomes.

How similar studies have performed: While previous studies have shown promising results for salvage cryoablation, this study aims to fill significant gaps in the evidence base, making it a novel and necessary investigation.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with local recurrence (with histological confirmation) after treatment with radiotherapy or brachytherapy without evidence of distant involvement evaluated with PET/PSMA (if not available then Fluciclovine PET/CT or choline PET/CT must be performed).
* Life expectancy \>10 years
* Prostate volume \< 100cc
* PSA\<10 ng/mL
* mpMRI + fusion/systematic biopsy ≤cT3a without affecting the bladder neck or the membranous urethra

Exclusion Criteria:

* Patients with clinically confirmed distant metastasis
* Any previous major rectal surgery
* Clinically significant lower urinary tract or rectal anomalies
* Existing urethral, rectal, or bladder fistulae

Where this trial is running

Córdoba, Andalucía and 1 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Prostate Cancer, Cryotherapy, Recurrent Prostate Cancer, PSMA/PET-CT

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.